









市场行情
/
股票
/
nasdaq-lenz
/

LENZ Therapeutics Inc

LENZ

16.890USD

-0.730-4.14%

收盘 12/23, 16:00（美东）报价延迟15分钟

482.86M总市值

亏损市盈率 TTM



LENZ Therapeutics Inc

16.890

-0.730-4.14%

概览公司财务分析

概览

公司

财务

分析

关于 LENZ Therapeutics Inc 公司

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

LENZ Therapeutics Inc简介



公司代码LENZ

公司名称LENZ Therapeutics Inc

上市日期Jun 25, 2021

CEOSchimmelpennink (Evert)

员工数量42

证券类型Ordinary Share

年结日Jun 25

公司地址- -

城市- -

上市交易所NASDAQ OMX - NASDAQ BASIC

国家- -

邮编- -

电话- -

网址- -

公司代码LENZ

上市日期Jun 25, 2021

CEOSchimmelpennink (Evert)

LENZ Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. James Mccollum

Independent Director

631.10K

+1.69%

Mr. Marc Odrich

Chief Medical Officer

99.60K

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

5.39K

+68.95%

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

Ms. Shelley B. Thunen

Independent Director

Dr. Frederic (Fred) Guerard, Pharm.D.

Independent Director

Jeff W. George

Independent Chairman of the Board

Mr. Evert (Eef) Schimmelpennink

President, Chief Executive Officer, Secretary, Director

名称

名称/职务

职务

持股

持股变动

Mr. James Mccollum

Independent Director

631.10K

+1.69%

Mr. Marc Odrich

Chief Medical Officer

99.60K

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

5.39K

+68.95%

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

RA Capital Management, LP

13.36%

Alpha Wave Global, LP

11.54%

Versant Ventures

8.49%

Ridgeback Capital Management, L.P.

6.24%

The Vanguard Group, Inc.

4.24%

其他

56.13%

持股股东

占比

RA Capital Management, LP

13.36%

Alpha Wave Global, LP

11.54%

Versant Ventures

8.49%

Ridgeback Capital Management, L.P.

6.24%

The Vanguard Group, Inc.

4.24%

其他

56.13%

股东类型

持股股东

占比

Venture Capital

34.49%

Investment Advisor

26.63%

Hedge Fund

23.81%

Investment Advisor/Hedge Fund

15.67%

Individual Investor

2.52%

Research Firm

2.01%

Pension Fund

0.17%

Bank and Trust

0.13%

Insurance Company

0.02%

机构持股



更新时间: 10月5日周日

报告期

机构数

持股数

持股占比

持股变动

2025Q3

267

30.95M

100.67%

+981.38K

2025Q2

245

29.52M

104.44%

-639.13K

2025Q1

245

28.95M

104.22%

-285.84K

2024Q4

225

27.65M

100.55%

-350.42K

2024Q3

204

26.43M

96.17%

-1.73M

2024Q2

197

25.06M

103.06%

+4.18M

2024Q1

204

22.41M

93.92%

+12.70M

2023Q4

200

7.73M

92.24%

-2.14M

2023Q3

200

7.54M

90.13%

-2.49M

2023Q2

212

7.64M

91.96%

-2.29M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

RA Capital Management, LP

4.18M

14.65%

Jun 30, 2025

Alpha Wave Global, LP

3.61M

12.66%

Jun 30, 2025

Versant Ventures

2.88M

10.1%

-135.30K

-4.48%

Sep 18, 2025

Ridgeback Capital Management, L.P.

1.95M

6.84%

Apr 14, 2025

The Vanguard Group, Inc.

1.29M

4.52%

+91.53K

+7.65%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.27M

4.44%

+216.45K

+20.60%

Jun 30, 2025

UBS Financial Services, Inc.

881.48K

3.09%

+214.32K

+32.12%

Jun 30, 2025

Paradigm BioCapital Advisors LP

1.72M

6.02%

+297.23K

+20.93%

Jun 30, 2025

72 Investment Holdings, LLC

1.02M

3.57%

Jun 30, 2025

Tang Capital Management, LLC

897.62K

3.15%

+130.68K

+17.04%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

State Street SPDR S&P Pharmaceuticals ETF

1.18%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.04%

Virtus LifeSci Biotech Clinical Trials ETF

0.68%

Invesco Dorsey Wright Healthcare Momentum ETF

0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

0.27%

iShares U.S. Pharmaceuticals ETF

0.22%

ProShares Ultra Nasdaq Biotechnology

0.11%

iShares Micro-Cap ETF

0.09%

Invesco Nasdaq Biotechnology ETF

0.08%

iShares Biotechnology ETF

0.06%

State Street SPDR S&P Pharmaceuticals ETF

占比1.18%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.04%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.68%

Invesco Dorsey Wright Healthcare Momentum ETF

占比0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.27%

iShares U.S. Pharmaceuticals ETF

占比0.22%

ProShares Ultra Nasdaq Biotechnology

占比0.11%

iShares Micro-Cap ETF

占比0.09%

Invesco Nasdaq Biotechnology ETF

占比0.08%

iShares Biotechnology ETF

占比0.06%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

公告日期

类型

比率

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

常见问题

LENZ Therapeutics Inc的前五大股东是谁？



LENZ Therapeutics Inc 的前五大股东如下：
RA Capital Management, LP持有股份：4.18M，占总股份比例：14.65%。
Alpha Wave Global, LP持有股份：3.61M，占总股份比例：12.66%。
Versant Ventures持有股份：2.88M，占总股份比例：10.10%。
Ridgeback Capital Management, L.P.持有股份：1.95M，占总股份比例：6.84%。
The Vanguard Group, Inc.持有股份：1.29M，占总股份比例：4.52%。